Patent SG-11201811064T-A (SG)
Title: Binding molecules binding pd-l1 and lag-3
Inventor: CAMPBELL JAMIE
IPC: C07K16/44
Filed: 2017-06-20
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 December 2017 (28.12.2017) WIPO I PCT ~~ll~~~~~~~~ 011101tIIl mum o Huts lionomo ow (10) International Publication Number WO 2017/220569 Al W O 20 17 / 2205 69 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 16/46 (2006.01) A61P 35/00 (2006.01) C07K 16/44 (2006.01) (21) International Application Number: PCT/EP2017/065073 (22) International Filing Date: 20 June 2017 (20.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/352,482 20 June 2016 (20.06.2016) US (71) Applicant: F-STAR DELTA LIMITED [GB/GB]; ED- DEVA B920, BABRAHAM RESEARCH CAMPUS, Cam- bridge, Cambridgeshire CB22 3AT (GB). (72) Inventors: CAMPBELL, Jamie; c/o KYMAB LIMITED, The Bennet Building (B930), Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT (GB). SANDY, Nikole; c/o KYMAB LIMITED, The Bennet Building (B930), Babraham Research Campus, Cambridge, Cam- bridgeshire CB22 3AT (GB). TUNA, Mihriban; c/o F-star Biotechnology Limited, Eddeva B920, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT (GB). WOLLERTON VAN HORCK, Francisca; c/o F-star Biotechnology Limited, Eddeva B920, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT (GB). EVERETT, Katy Louise; c/o F-star Biotechnology Limit- ed, Eddeva B920, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT (GB). GASPAR, Miguel; c/ o F-star Biotechnology Limited, Eddeva B920, Babra- ham Research Campus, Cambridge, Cambridgeshire CB22 3AT (GB). KRAMAN, Matthew; c/o F-star Biotechnol- ogy Limited, Eddeva B920, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT (GB). KMIECIK, Katarzyna; c/o F-star Biotechnology Limited, Eddeva B920, Babraham Research Campus, Cambridge, Cam- bridgeshire CB22 3AT (GB). FAROUDI, Mustapha; c/ o F-star Biotechnology Limited, Eddeva B920, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT (GB). FOSH, Natalie; c/o F-star Biotechnology Limited, Eddeva B920, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT (GB). HEBEIS, Barbara; c/ o F-star Biotechnology Limited, Eddeva B920, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT (GB). (74) Agent: KEIRSTEAD, Tanis et al.; Mewburn Ellis LLP, City Tower, 40 Basinghall Street, London, Greater London EC2V 5DE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: BINDING MOLECULES BINDING PD-L1 AND LAG-3 (57) : The present disclosure relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lympho- cyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the disclosure fmd application, for example, in cancer therapy.